Cheng Hsin General Hospital’s Heart Team Awarded ‘Symbol of National Quality’ for Excellence in Carotid Artery Stenting with Mo.Ma Proximal Embolic Protection Device

Approximately 80% of stroke patients experience ischemic strokes, largely attributed to carotid artery stenosis. Following a thorough evaluation by physicians, carotid artery stenting is often recommended to alleviate symptoms and diminish the risk of stroke.

Traditionally, carotid artery stenosis is managed with balloon angioplasty and subsequent stent placement. However, this method poses a risk of distal embolization, potentially leading to transient ischemic attacks or strokes. To reduce this risk, embolic protection devices (EPDs) have been developed.

There are primarily two types of EPDs: conventional distal filter devices and proximal protection devices like the Mo.Ma system. Conventional distal filters effectively capture larger particles (>100 micrometers), but smaller particles can still pass through. These devices also require precise positioning and may face difficulties navigating tortuous carotid arteries, thereby leaving the brain unprotected during the procedure.

In contrast, proximal protection devices like the Mo.Ma system employ dual balloons that are inflated in the common carotid artery and the external carotid artery, blocking both antegrade and retrograde blood flow. Functioning similarly to vascular clamps, these balloons provide comprehensive brain protection during the procedure. To ensure the success of the surgery and the safety of the patient, stagnant blood, impurities, and particles are aspirated before they can enter the brain, effectively preventing cerebral vascular embolization and reducing the risk of stroke. As a result, the Mo.Ma system is recognized as the preferred standard for most carotid artery stenting procedures at our hospital.

Since 2016, Cheng Hsin General Hospital has successfully performed 294 carotid artery stenting procedures, with nearly half using the Mo.Ma system. The surgeries have achieved a 99% success rate, with an exceptionally low stroke rate of 2.8%. In recognition of our high standards and outstanding outcomes, we were honored to receive the ‘Symbol of National Quality’ (SNQ) award in December 2023.